Spinal Tuberculosis (STB) represents between 1% and 2% of total tuberculosis cases. STB management remains challenging; the first-line approach consists of medical treatment, while surgery is reserved for patients with complications. No data regarding STB treatment with bedaquiline-containing regimens are available in the literature.
Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report / De Vito, A., Fiore, V., Urru, V., Bozzi, E., Geremia, N., Princic, E., Canu, D., Molicotti, P., Are, R., Babudieri, S., Madeddu, G.. - In: THE BRAZILIAN JOURNAL OF INFECTIOUS DISEASES. - ISSN 1413-8670. - (2022). [10.1016/j.bjid.2022.102701]
Use of bedaquiline in spinal osteomyelitis and soft tissue abscess caused by multidrug-resistant Mycobacterium tuberculosis: A case report
De Vito, Andrea
;Fiore, Vito;Urru, Valentina;Bozzi, Elena;Geremia, Nicholas;Princic, Elija;Molicotti, Paola;Babudieri, Sergio;Madeddu, Giordano
2022-01-01
Abstract
Spinal Tuberculosis (STB) represents between 1% and 2% of total tuberculosis cases. STB management remains challenging; the first-line approach consists of medical treatment, while surgery is reserved for patients with complications. No data regarding STB treatment with bedaquiline-containing regimens are available in the literature.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
